Outstanding Care, Compassionate People, Healthier Communities

Direct Line: 01623 672232 Our Ref: 482 E-mail: <u>sfh-tr.foi.requests@nhs.net</u>

30th January 2025

King's Mill Hospital Mansfield Road Sutton in Ashfield Nottinghamshire NG17 4JL

Tel: 01623 622515 Join today: www.sfh-tr.nhs.uk

Dear Sir/Madam

Freedom of Information Act (FOI) 2000 - Request for Information Reference: Treatment for Asthma Aug-Nov 24

I am writing in response to your request for information under the FOI 2000.

I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below. Please accept our sincere apologies for the delay.

Home, Community, Hospital.

Patient Experience Team 01623 672222 sfh-tr.pet@nhs.net



FOI Request / Question	Question Response	Is there an exemption?	Exemption	Exemption Details
1. How many patients have been treated (for any condition) Aug-	Dupilumab – 29			
Nov 24 with:	Mepolizumab – 2			
Benralizumab	Omalizumab – 33			
• Dupilumab				
Omalizumab				
Reslizumab				
Mepolizumab				
Tezepelumab				
2. Of the patients treated Aug-Nov 24 with any of the above	Dupilumab -			
products, please provide the number of patients by the following	Age 6-11 – 0			
age-groups:	Age 12-17 – 0			
• Age 6-11	Age 18 and above – 29			
• Age 12-17				
Age 18 and above	Mepolizumab -			
	Age 6-11 – 1			
	Age 12-17 – 0			
	Age 18 and above – 1			
	Omalizumab -			
	Age 6-11 – 0			
	Age 12-17 – 1			
	Age 18 and above – 32			

2

Home, Community, Hospital.

Patient Experience Team 01623 672222 sfh-tr.pet@nhs.net



We are proud to be a smoke-free site Acting Chair Graham Ward Acting Chief Executive David Selwyn

3. How many patients have been treated Aug-Nov 24 by the	No support needed, See below response		
Respiratory Medicine department ONLY with:Dupilumab	Omalizumab – 25		
• Omalizumab	Nil for others		
4. How many patients have been diagnosed with BOTH chronic	53 inpatients coded with both J32 & J33.		
sinusitis (ICD-10 code J32) & nasal polyps (ICD-10 code J33) in	Discharge date in 2024. Inpatients only.		
the past year?			
5. Of these patients from Q4, how many have been treated Aug-	1 patient with Omalizumab (Discharge and		
Nov 24 with:	issue date between August 24 and November		
Benralizumab	24.		
• Dupilumab			
• Omalizumab			
Reslizumab			
Mepolizumab			
Tezepelumab			

Home, Community, Hospital.

Patient Experience Team 01623 672222 sfh-tr.pet@nhs.net



We are proud to be a smoke-free site Acting Chair Graham Ward Acting Chief Executive David Selwyn

3

I trust this information answers your request. Should you have any further enquiries or queries about this response please do not hesitate to contact me. However, if you are unhappy with the way in which your request has been handled, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Sally Brook Shanahan, Director of Corporate Affairs, King's Mill Hospital, Mansfield Road, Sutton in Ashfield, Nottinghamshire, NG17 4JL or email sally.brookshanahan@nhs.net.

If you are dissatisfied with the outcome of the internal review, you can apply to the Information Commissioner's Office, who will consider whether we have complied with our obligations under the Act and can require us to remedy any problems. Generally, the Information Commissioner's Office cannot decide unless you have exhausted the internal review procedure. You can find out more about how to do this, and about the Act in general, on the Information Commissioner's Office website at: <u>https://ico.org.uk/your-data-matters/official-information/</u>.

Complaints to the Information Commissioner's Office should be sent to FOI/EIR Complaints Resolution, Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. Telephone 0303 1231113, email <u>casework@ico.org.uk</u>.

If you would like this letter or information in an alternative format, for example large print or easy read, or if you need help with communicating with us, for example because you use British Sign Language, please let us know. You can call us on 01623 672232 or email <u>sfh-tr.foi.requests@nhs.net</u>.

Yours faithfully

Information Governance Team

All information we have provided is subject to the provisions of the Re-use of Public Sector Information Regulations 2015. Accordingly, if the information has been made available for reuse under the <u>Open Government Licence</u> (OGL) a request to re-use is not required, but the licence conditions must be met. You must not re-use any previously unreleased information without having the consent from Sherwood Forest Hospitals NHS Foundation Trust. Should you wish to re-use previously unreleased information then you must make your request in writing. All requests for re-use will be responded to within 20 working days of receipt.

4

Home, Community, Hospital.

Patient Experience Team 01623 672222 sfh-tr.pet@nhs.net



We are proud to be a smoke-free site Acting Chair Graham Ward Acting Chief Executive David Selwyn